Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRITON-PN: Phase 3 study of Nucresiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy
jRCT2031250851Phase 3Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Mar 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Phase 3, randomised, open-label trial of nucresiran in hereditary transthyretin amyloidosis (hATTR) (2 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Change from baseline in mNIS+7 at Month 9 vs external placebo. Started Mar 2026; status: recruiting.
02
Drugs
nucresiran
03
Conditions
hereditary transthyretin amyloidosis (hATTR)
Beyond the preview
Go deeper on jRCT2031250851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250851.